USpolicy

News

US Treasury proposes curbs on Chinese biotech deals

China has emerged as a major source of drug candidates for pharma groups, but a new proposal by the US Treasury could slam the brakes on future deals.

News

Despite US policy changes, drug prices stay stubbornly high

US policy changes designed to curb drug prices seem ineffective, as the annual cost of new medicines still exceeds $250,000, curbing patient access.

News

Compounded tirzepatide recalled after FDA warning

A compounded version of Eli Lilly's injectable weight-loss and diabetes therapy tirzepatide has been recalled from sale due to sterility concerns.

News

FTC says Shkreli is flouting lifetime pharma ban

The FTC and several US states have accused Martin Shkreli of violating a lifetime order preventing him from involvement in the pharma industry.

Market Access

Magnifying glass over pills scattered over dollar and euro notes

One year after MFN: How US policy is reshaping the global ph...

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards MFN pricing.

News

PhRMA sues Trump administration over GLOBE rebate scheme

PhRMA is challenging the Trump administration's GLOBE model for Most-Favoured Nation pricing in Medicare Part B in a US district court.

US Treasury proposes curbs on Chinese biotech deals

Despite US policy changes, drug prices stay stubbornly high

Compounded tirzepatide recalled after FDA warning

FTC says Shkreli is flouting lifetime pharma ban

One year after MFN: How US policy is reshaping the global ph...

PhRMA sues Trump administration over GLOBE rebate scheme

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

USpolicy

Editor's Picks